Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
Status:
Recruiting
Trial end date:
2026-08-23
Target enrollment:
Participant gender:
Summary
This is a single arm, open label, phase II clinical trial. Adult patients with hematological
malignancies undergoing allogeneic HSCT from first- or second-degree haploidentical donor are
eligible for the study if they meet the standard criteria defined in our institutional
standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any
exclusion criteria. Patients will receive non-myeloablative, reduced-intensity or
myeloablative conditioning regimen followed by peripheral blood hematopoietic stem cells.
Patients will receive dosed reduced cyclophosphamide, abatacept, and short-duration
tacrolimus for GvHD prophylaxis.